SubHero Banner
Text

Linagliptin-containing products (Glyxambi®, Jentadueto®, Jentadueto XR®, Tradjenta® ) – New Warning

December 23, 2016 – The FDA approved a new update to the Warnings and Precautions section of the Glyxambi (empagliflozin/linagliptin), Jentadueto (linagliptin/metformin), Jentadueto XR (linagliptin/metformin extended-release), and Tradjenta (linagliptin) drug labels regarding bullous pemphigoid.

Download PDF